{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:04:50Z","timestamp":1793775890395,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adoptive T cell therapy using chimeric antigen receptor (CAR) engineered T cells is currently being explored in multiple cancer types beyond leukemia\/lymphoma. A key step in CAR-T cell manufacturing is the activation and expansion of T cells, which facilitates viral transduction, however, may hamper T cell fitness and reduce in vivo persistence. \u201cT-Expand\u201d is developed for T cell activation and expansion, comprising dextran-based nanoparticles conjugated with anti-CD3 and anti-CD28 antibodies. The nanoparticles trigger robust polyclonal expansion of human T cells with efficiency in the range of commercial microbeads (Dynabeads\u2122). Engineered in the presence of T-Expand, CD19 CAR T cells display enhanced proliferative capacity, cytotoxicity and persistence in vitro, and furthermore, exhibit potent anti-lymphoma activity in mouse models, resulting in complete tumor clearance at one fourth of the CAR T cell dose. Importantly, T-Expand is biocompatible with no observed toxicity, circumventing removal steps after T cell expansion compared to Dynabeads\n                    <jats:sup>TM<\/jats:sup>\n                    . As a biocompatible T cell expansion platform, T-Expand simplifies the manufacturing process while enhancing T cell persistence and functionality, and thereby holds promise for increasing clinical efficacy of CAR T cell therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-67868-1","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:16:16Z","timestamp":1768886176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-4344","authenticated-orcid":false,"given":"Tao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9169","authenticated-orcid":false,"given":"Keerthana","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ormh\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Rasmus","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00f3lmfridur R\u00f3sa","family":"Halld\u00f3rsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-8119","authenticated-orcid":false,"given":"Hanxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-7142","authenticated-orcid":false,"given":"Kamilla Kj\u00e6rgaard","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5079-5344","authenticated-orcid":false,"given":"Carlos","family":"Rodriguez-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Ulslev Wegener","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4506-4932","authenticated-orcid":false,"given":"Peter M. H.","family":"Heegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-0260","authenticated-orcid":false,"given":"Klaus","family":"Qvortrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0210-4730","authenticated-orcid":false,"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-4344","authenticated-orcid":false,"given":"Sine Reker","family":"Hadrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"67868_CR1","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s12094-024-03774-0","volume":"27","author":"XJ Yu","year":"2025","unstructured":"Yu, X. J. et al. Application of CAR-T cell therapy in B-cell lymphoma: a meta-analysis of randomized controlled trials. Clin. Transl. Oncol. 27, 2700\u20132709 (2025).","journal-title":"Clin. Transl. Oncol."},{"key":"67868_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"67868_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"67868_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903562","volume":"13","author":"P Kandra","year":"2022","unstructured":"Kandra, P. et al. Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in Lung cancer. Front. Immunol. 13, 903562 (2022). Article.","journal-title":"Front. Immunol."},{"key":"67868_CR5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J. Exp. Med. 221, e20230903 (2024).","journal-title":"J. Exp. Med."},{"key":"67868_CR6","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.1016\/S2352-3026(24)00273-4","volume":"12","author":"G Agliardi","year":"2025","unstructured":"Agliardi, G., Dias, J., Rampotas, A., Garcia, J. & Roddie, C. Accelerating and optimising CAR T-cell manufacture to deliver better patient products.  Lancet Haematol. 12, E57\u2013E67 (2025).","journal-title":"Lancet Haematol."},{"key":"67868_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","volume":"18","author":"U Mock","year":"2016","unstructured":"Mock, U. et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18, 1002\u20131011 (2016).","journal-title":"Cytotherapy"},{"key":"67868_CR8","doi-asserted-by":"crossref","unstructured":"Kagoya, Y. et al. Transient stimulation expands superior antitumor T cells for adoptive therapy. JCI Insight 2, e89580 (2017).","DOI":"10.1172\/jci.insight.89580"},{"key":"67868_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nbt.4047","volume":"36","author":"AS Cheung","year":"2018","unstructured":"Cheung, A. S., Zhang, D. K. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 36, 160\u2013169 (2018).","journal-title":"Nat. Biotechnol."},{"key":"67868_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41551-024-01216-4","volume":"9","author":"DKY Zhang","year":"2025","unstructured":"Zhang, D. K. Y. et al. Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells. Nat. Biomed. Eng. 9, 268\u2013278 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"67868_CR11","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/s41565-024-01781-4","volume":"19","author":"E Zhu","year":"2024","unstructured":"Zhu, E. et al. Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies. Nat. Nanotechnol. 19, 1914\u20131922 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"67868_CR12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/s41551-024-01272-w","volume":"8","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies. Nat. Biomed. Eng. 8, 1615\u20131633 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"67868_CR13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cels.2024.11.007","volume":"15","author":"E Ariail","year":"2024","unstructured":"Ariail, E., Garcia Espinoza, N., Stephenson, A. C. & Spangler, J. B. Emerging approaches for T cell-stimulating platform development. Cell Syst. 15, 1198\u20131208 (2024).","journal-title":"Cell Syst."},{"key":"67868_CR14","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1073\/pnas.0901592106","volume":"14","author":"KE Broaders","year":"2009","unstructured":"Broaders, K. E., Cohen, J. A., Beaudette, T. T., Bachelder, E. M. & Fr\u00e9 Chet, J. M. J. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc. Natl. Acad. Sci. USA 14, 5497\u20135502 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67868_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201603239","volume":"29","author":"F Fontana","year":"2017","unstructured":"Fontana, F. et al. Multistaged nanovaccines based on porous silicon@acetalated dextran@cancer cell membrane for cancer immunotherapy. Adv. Mater. 29, 1603239 (2017).","journal-title":"Adv. Mater."},{"key":"67868_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49804-x","volume":"15","author":"H Gao","year":"2024","unstructured":"Gao, H. et al. Comparative optimization of polysaccharide-based nanoformulations for cardiac RNAi therapy. Nat. Commun. 15, 5398 (2024).","journal-title":"Nat. Commun."},{"key":"67868_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1021\/bc100596w","volume":"22","author":"L Cui","year":"2011","unstructured":"Cui, L., Cohen, J. A., Broaders, K. E., Beaudette, T. T. & Fr\u00e9chet, J. M. J. Mannosylated dextran nanoparticles: A pH-sensitive system engineered for immunomodulation through mannose targeting. Bioconjug. Chem. 22, 949\u2013957 (2011).","journal-title":"Bioconjug. Chem."},{"key":"67868_CR18","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1039\/D3MH00717K","volume":"10","author":"SK Filippov","year":"2023","unstructured":"Filippov, S. K. et al. Dynamic light scattering and transmission electron microscopy in drug delivery: a roadmap for correct characterization of nanoparticles and interpretation of results. Mater. Horiz. 10, 5354\u20135370 (2023).","journal-title":"Mater. Horiz."},{"key":"67868_CR19","doi-asserted-by":"crossref","unstructured":"Kim, A., Ng, W. B., Bernt, W. & Cho, N. J. Validation of size estimation of nanoparticle tracking analysis on polydisperse macromolecule assembly. Sci Rep. 9, 2639 (2019).","DOI":"10.1038\/s41598-019-38915-x"},{"key":"67868_CR20","first-page":"616","volume":"5","author":"MP Nanut","year":"2014","unstructured":"Nanut, M. P., Saboti\u010d, J., Jewett, A. & Kos, J. Cysteine cathepsins as regulators of the cytotoxicity of NK and T cells. Front. Immunol. 5, 616 (2014).","journal-title":"Front. Immunol."},{"key":"67868_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng, B. et al. The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature 634, 712\u2013720 (2024).","journal-title":"Nature"},{"key":"67868_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter, S. A. et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature 630, 457\u2013465 (2024).","journal-title":"Nature"},{"key":"67868_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"67868_CR24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","volume":"7","author":"AQ Zhang","year":"2023","unstructured":"Zhang, A. Q. et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat. Biomed. Eng. 7, 1113\u20131128 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"67868_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36126-7","volume":"14","author":"DKY Zhang","year":"2023","unstructured":"Zhang, D. K. Y. et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat. Commun. 14, 506 (2023).","journal-title":"Nat. Commun."},{"key":"67868_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27613-w","volume":"12","author":"I Otano","year":"2021","unstructured":"Otano, I. et al. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat. Commun. 12, 7296 (2021).","journal-title":"Nat. Commun."},{"key":"67868_CR27","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/2159-8290.CD-21-1508","volume":"12","author":"TL Wilson","year":"2022","unstructured":"Wilson, T. L. et al. Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. Cancer Discov. 12, 2098\u20132119 (2022).","journal-title":"Cancer Discov."},{"key":"67868_CR28","doi-asserted-by":"publisher","first-page":"e010581","DOI":"10.1136\/jitc-2024-010581","volume":"13","author":"X-N Li","year":"2025","unstructured":"Li, X.-N. et al. XCL1-secreting CEA CAR-T cells enhance endogenous CD8 + T cell responses to tumor neoantigens to confer a long-term antitumor immunity. J. Immunother. Cancer 13, e010581 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"67868_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical Role for CD103+\/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"67868_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41423-020-0481-0","volume":"17","author":"J Qiao","year":"2020","unstructured":"Qiao, J. & Fu, Y.-X. Cytokines that target immune killer cells against tumors. Cell Mol. Immunol. 17, 722\u2013727 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"67868_CR31","doi-asserted-by":"publisher","first-page":"100543","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng, J., Comerford, I. & McColl, S. R. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep. Med 3, 100543 (2022).","journal-title":"Cell Rep. Med"},{"key":"67868_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/84205","volume":"2","author":"SA Luther","year":"2001","unstructured":"Luther, S. A. & Cyster, J. G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2, 102\u2013107 (2001).","journal-title":"Nat. Immunol."},{"key":"67868_CR33","doi-asserted-by":"publisher","first-page":"15072","DOI":"10.1021\/acsnano.2c06211","volume":"16","author":"AC Wauters","year":"2022","unstructured":"Wauters, A. C. et al. Artificial antigen-presenting cell topology dictates T cell activation. ACS Nano 16, 15072\u201315085 (2022).","journal-title":"ACS Nano"},{"key":"67868_CR34","doi-asserted-by":"publisher","first-page":"111643","DOI":"10.1016\/j.intimp.2024.111643","volume":"129","author":"S Weller","year":"2024","unstructured":"Weller, S. et al. Influence of different conjugation methods for activating antibodies on polymeric nanoparticles: Effects for polyclonal expansion of human CD8+ T cells. Int Immunopharmacol. 129, 111643 (2024).","journal-title":"Int Immunopharmacol."},{"key":"67868_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202303940","volume":"19","author":"D Mateus","year":"2023","unstructured":"Mateus, D. et al. Artificial Dendritic Cells: A New Era of Promising Antitumor Immunotherapy. Small 19, 2303940 (2023).","journal-title":"Small"},{"key":"67868_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1189\/jlb.0603298","volume":"80","author":"DT Shen","year":"2006","unstructured":"Shen, D. T., Ma, J. S. Y., Mather, J., Vukmanovic, S. & Radoja, S. Activation of primary T lymphocytes results in lysosome development and polarized granule exocytosis in CD4+ and CD8+ subsets, whereas expression of lytic molecules confers cytotoxicity to CD8+ T cells. J. Leukoc. Biol. 80, 827\u2013837 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"67868_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/80877","volume":"1","author":"Jenny Hendriks","year":"2000","unstructured":"Hendriks, J. enny et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1, 433\u2013440 (2000).","journal-title":"Nat. Immunol."},{"key":"67868_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto, S. et al. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21\u201333 (2024).","journal-title":"Blood Cancer Discov."},{"key":"67868_CR39","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 3, 2812\u20132815 (2019).","journal-title":"Blood Adv."},{"key":"67868_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","volume":"1","author":"DJ Powell","year":"2005","unstructured":"Powell, D. J., Dudley, M. E., Robbins, P. F. & Rosenberg, S. A. Transition of late-stage effector T cells to CD27 CD28 tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 1, 241\u2013250 (2005).","journal-title":"Blood"},{"key":"67868_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2024.01.011","volume":"57","author":"CA Jaeger-Ruckstuhl","year":"2024","unstructured":"Jaeger-Ruckstuhl, C. A. et al. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity 57, 287\u2013302 (2024).","journal-title":"Immunity"},{"key":"67868_CR42","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"67868_CR43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","journal-title":"Nat. Biotechnol."},{"key":"67868_CR44","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"67868_CR45","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med 24, 739\u2013748 (2018).","journal-title":"Nat. Med"},{"key":"67868_CR46","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter. Nat. Med 24, 731\u2013738 (2018).","journal-title":"Nat. Med"},{"key":"67868_CR47","doi-asserted-by":"crossref","unstructured":"Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463\u20138471 (1998).","DOI":"10.1128\/JVI.72.11.8463-8471.1998"},{"key":"67868_CR48","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1158\/0008-5472.CAN-11-1562","volume":"71","author":"B Guan","year":"2011","unstructured":"Guan, B., Wang, T. L. & Shih, I. M. ARID1A, a factor that promotes formation of SWI\/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71, 6718\u20136727 (2011).","journal-title":"Cancer Res"},{"key":"67868_CR49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"67868_CR50","doi-asserted-by":"crossref","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","DOI":"10.1186\/s13059-014-0550-8"},{"key":"67868_CR51","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"67868_CR52","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67868-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:05:34Z","timestamp":1769612734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67868-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67868"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67868-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors T.Z., K.R., M.O., H.R.H., Y.S., and S.R.H. are part of the patent application Dextran nanoparticles for T-cell activation and proliferation. European Patent Application No. 24178957.7. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1103"}}